Skip to Content
Stock Analyst Update

FDA Announces Plan to Ban Menthol

We plan to lower our tobacco valuations by mid-single-digit amounts.

Mentioned:

Altria's (MO) in line first-quarter results were overshadowed by the Food and Drug Administration's announcement that it is to seek a ban on menthol cigarettes. Although the risk of a menthol ban has been a long-term overhang and one of the ESG risks we have identified, we did not include it in our base-case assumptions because we felt the legal burden of proof for implementing a ban--which required the FDA to prove that a ban would be a net public health benefit--was fairly high. Following the FDA's announcement, however, we believe the probability of a ban has now increased because the FDA clearly believes it has met that burden of proof. We still believe a ban will take years to implement, and we are lowering our stage II growth rate assumptions for the cigarette makers with exposure to the menthol category in the U.S. We are lowering our fair value estimates of Altria to $52 per share from $54, of British American Tobacco to GBX 4,000 from 4,300, and of Imperial Brands to GBX 2,900 from GBX 3,000. We believe the tobacco group remains undervalued, and our picks remain Philip Morris International, whose exposure to the U.S. is limited to a revenue share of its market-leading reduced risk portfolio, and Imperial Brands, which trades at under 10 times forward earnings and pays a dividend yield of 9%.

Altria's first-quarter revenue net of excise taxes fell by 3.3%, slightly worse than our forecast due to a steep 12% decline in cigarette volume. We do not think that the underlying volume trend of a roughly 4% decline rate has changed much, however, and with management reiterating full-year guidance, it is likely that trade inventory movements drove volumes lower and that the impact of inventory level changes will reverse throughout the remainder of the year. Nevertheless, we expect the gradual easing of social distancing measures to slow volumes in the coming quarters. We retain our full-year estimates at the high end of management's EPS guidance of $4.49 to $4.62.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Philip Gorham does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.